DA
PTCT icon

Duality Advisers’s PTC Therapeutics PTCT Stock Holding History

Duality Advisers’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-49,322
Closed -$1.43M – 416
2024
Q1 		$1.43M Buy
49,322
+2,724
+6% +$76.3K 0.14% 246
2023
Q4 		$1.28M Buy
46,598
+10,625
+30% +$243K 0.14% 262
2023
Q3 		$806K Buy
35,973
+145
+0.4% +$5.39K 0.1% 335
2023
Q2 		$1.46M Buy
35,828
+25,800
+257% +$1.26M 0.18% 217
2023
Q1 		$486K Sell
10,028
-23,432
-70% -$1.07M 0.06% 415
2022
Q4 		$1.28M Sell
33,460
-1,697
-5% -$70.5K 0.15% 254
2022
Q3 		$1.76M Buy
+35,157
New +$1.72M 0.19% 212
2022
Q2 		– Sell
-22,330
Closed -$833K – 816
2022
Q1 		$833K Buy
22,330
+14,607
+189% +$563K 0.09% 370
2021
Q4 		$308K Sell
7,723
-18,197
-70% -$696K 0.03% 443
2021
Q3 		$964K Buy
25,920
+16,809
+184% +$690K 0.07% 361
2021
Q2 		$385K Sell
9,111
-45,839
-83% -$1.96M 0.03% 455
2021
Q1 		$2.6M Buy
54,950
+33,316
+154% +$1.98M 0.23% 146
2020
Q4 		$1.32M Buy
21,634
+574
+3% +$33.8K 0.1% 296
2020
Q3 		$985K Buy
+21,060
New +$1.04M 0.06% 373

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Duality Advisers's PTCT Position: Q2 2024 in Review

Duality Advisers sold out of PTC Therapeutics (PTCT) in Q2 2024, closing a stake of 49,322 shares — an estimated $1.43M sold.

Duality Advisers first reported a position in PTCT in Q3 2020 and held it in 14 quarters. The position peaked at $2.6M in Q1 2021. 198 funds tracked by Wall St. Rank hold PTCT as of Q2 2024.

  • Duality Advisers reported no remaining PTC Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Duality Advisers sold 49,322 PTC Therapeutics shares in Q2 2024, an estimated $1.43M.
  • Duality Advisers first reported a position in PTC Therapeutics in Q3 2020 and held it in 14 quarters.
  • Duality Advisers's PTC Therapeutics position peaked at $2.6M in Q1 2021.
  • 198 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2024.

Based on Duality Advisers's 13F filing for Q2 2024.